Should a serum neural-antibody result be interpreted with the clinical syndrome and confirmatory testing?

A serum neural-antibody result is clinically meaningful only when it fits a compatible neurologic syndrome and is supported by appropriate confirmatory evaluation. This is particularly important in an older adult, in whom diagnostic attribution can substantially affect immunotherapy decisions and malignancy evaluation.

Clinical evidence

• Serum positivity alone does not establish autoimmune or paraneoplastic neurologic disease. Interpretation should incorporate the syndrome’s tempo and phenotype, MRI, EEG, CSF routine/inflammatory and infectious studies, and exclusion of plausible alternatives.
• Diagnostic performance is strongly antigen- and assay-dependent. Reported positive predictive values for serum intracellular/onconeural antibodies range from 25% to 80%.
• In a high-risk paraneoplastic cohort, only 4 of 50 (8%) line-blot-positive, tissue-assay-negative samples were confirmed as true positives, versus 91% confirmation when results were concordant with tissue-based immunofluorescence. This demonstrates that isolated commercial-assay findings can be misleading.

Confirmatory and target-specific considerations

• Paired serum–CSF testing and orthogonal confirmation—such as tissue-based screening plus antigen-specific cell-based assay or immunoblot—materially improve diagnostic credibility, especially for low-titer/weak serum results or atypical presentations.
• CSF is particularly clinically sensitive and specific for NMDAR antibodies and is important for confirmation; GFAP is likewise more informative in CSF. Conversely, LGI1 and some CASPR2 presentations may be serum-predominant.
• Low serum GAD65 titers may be nonspecific, and isolated VGKC positivity is not sufficiently disease-specific unless LGI1 or CASPR2 antibodies are identified.

Bottom line

• A serum-only neural-antibody result should refine—not replace—syndrome-based diagnosis. Concordance among the clinical phenotype, paired serum/CSF findings, and an independent assay offers the strongest basis for attributing neurologic symptoms to antibody-associated autoimmunity.